Rockwell Medical (RMTI)
(Real Time Quote from BATS)
$3.91 USD
-0.25 (-5.90%)
Updated Sep 13, 2024 10:22 AM ET
1-Strong Buy of 5 1
C Value A Growth D Momentum B VGM
Brokerage Reports
Rockwell Medical, Inc. [RMTI]
Reports for Purchase
Showing records 221 - 240 ( 242 total )
Company: Rockwell Medical, Inc.
Industry: Medical - Products
PRIME Phase II Study of SFP Completes Patient Enrollment
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Rockwell Medical, Inc.
Industry: Medical - Products
Initiating Coverage with a Market Outperform Rating; $16 Price Target
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Rockwell Medical, Inc.
Industry: Medical - Products
Initiating Coverage with a Market Outperform Rating; $16 Price Target
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Rockwell Medical, Inc.
Industry: Medical - Products
Uneventful Earnings; On Track For Eventful Next 12 Months
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Rockwell Medical, Inc.
Industry: Medical - Products
Cumulative safety data from ongoing CRUISE studies reveals no concerns.
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Rockwell Medical, Inc.
Industry: Medical - Products
Company: Rockwell Medical, Inc.
Industry: Medical - Products
Current Share Price Represents Attractive Entry Point for Investors with a 12-18 Month Time Horizon
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Rockwell Medical, Inc.
Industry: Medical - Products
Company: Rockwell Medical, Inc.
Industry: Medical - Products
Company: Rockwell Medical, Inc.
Industry: Medical - Products
Company: Rockwell Medical, Inc.
Industry: Medical - Products
LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of March 6
Provider: WEDBUSH SECURITIES INC.
Company: Rockwell Medical, Inc.
Industry: Medical - Products
Q4:2010 Results; Expect Imminent Enrollment in Phase III SFP Trials; Raising FV to $12 from $10
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Rockwell Medical, Inc.
Industry: Medical - Products
Company: Rockwell Medical, Inc.
Industry: Medical - Products
Company: Rockwell Medical, Inc.
Industry: Medical - Products
Company: Rockwell Medical, Inc.
Industry: Medical - Products
Company: Rockwell Medical, Inc.
Industry: Medical - Products
Phase III SFP Trial Design Finalized; Initiation Expected Within 90 Days
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Rockwell Medical, Inc.
Industry: Medical - Products
Profitable Q2:10; New Details Incrementally De-risk the Upcoming Phase III SFP Trial.
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Rockwell Medical, Inc.
Industry: Medical - Products
Q1:10 Cash Flow Positive; Potential Phase IIB SFP Data Presentation in June
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Rockwell Medical, Inc.
Industry: Medical - Products
Company Taking Steps to Improve Execution of Phase III Trial; All Eyes on Phase III Trial Design
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D